Clinical Trial Update: A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. [Phase 3]

View source ↗

Summary

Clinical trial update for SHR-1210 (anti-PD-1) + FOLFOX4 in advanced hepatocellular carcinoma; Phase 3 study with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• FOLFOX4 (Folinic acid (Leucovorin), Fluorouracil (5-FU), Oxaliplatin)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Advanced Hepatocellular Carcinoma | Phase 3 | Status: UNKNOWN